Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.
ACT, Asthma Control Test
BMI, Body Mass Index
DREAM, Dose Ranging Efficacy And safety with Mepolizumab
EA, Eosinophilic Asthma
ECRS, Eosinophilic Chronic Rhinosinusitis
ERS/ATS, European Respiratory Society/American Thoracic Society
FEV1, Forced Expiratory Volume in 1 s
FEV1/FVC, Forced Expiratory Volume in 1 s/Forced Vital Capacity ratio
FVC, Forced Vital Capacity
GERD, Gastro-Esophageal Reflux Disease
GINA, Global INitiative for Asthma
IL-5, Interleukin-5
IQR, Interquartile Range
IgG, Immunoglobulin G
MEPO, Mepolizumab
Mepolizumab
Multiple comorbidities
NARES, Non Allergic Rhinitis with Eosinophilia Syndrome
OCS, Oral Corticosteroid
RCTs, Randomized Controlled Trials
RV, Residual Volume
SD, Standard Deviation
SEM, Standard Error Mean
Severe eosinophilic asthma
T0, baseline
T1, 3 months after baseline
T12, 12 months after baseline
T3, 6 months after baseline
T6, 9 months after baseline
Journal
The World Allergy Organization journal
ISSN: 1939-4551
Titre abrégé: World Allergy Organ J
Pays: United States
ID NLM: 101481283
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
26
02
2020
revised:
27
08
2020
accepted:
31
08
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
1
10
2020
Statut:
epublish
Résumé
Data on mepolizumab in patients with severe eosinophilic asthma (EA) and comorbidities are needed to assess whether randomized controlled trial results are applicable in the real world. To evaluate real-life effectiveness and the presence/absence of predictors of treatment response in patients with one or more comorbidities (nasal polyps, allergic rhinitis, gastro-esophageal reflux disease, nonallergic rhinitis with eosinophilia syndrome, obesity, bronchiectasis) who received mepolizumab (MEPO) for the treatment of severe EA. We performed a single-center retrospective study in patients with severe asthma and presence of comorbidities treated with mepolizumab at the respiratory outpatient clinic, Policlinico-Vittorio Emanuele, Catania, Italy. Health records of 31 severe asthmatic patients were retrieved and analyzed. Asthma control test (ACT) score, blood eosinophil count, forced expiratory volume in 1 s (FEV 83.87% of patients were classified as responsive to MEPO treatment. Substantial depletion of the blood eosinophils (>80%) was found in 87.1% of patients, FEV MEPO in patients with severe EA is effective regardless of the presence of comorbidities.
Sections du résumé
BACKGROUND
BACKGROUND
Data on mepolizumab in patients with severe eosinophilic asthma (EA) and comorbidities are needed to assess whether randomized controlled trial results are applicable in the real world.
OBJECTIVE
OBJECTIVE
To evaluate real-life effectiveness and the presence/absence of predictors of treatment response in patients with one or more comorbidities (nasal polyps, allergic rhinitis, gastro-esophageal reflux disease, nonallergic rhinitis with eosinophilia syndrome, obesity, bronchiectasis) who received mepolizumab (MEPO) for the treatment of severe EA.
METHODS
METHODS
We performed a single-center retrospective study in patients with severe asthma and presence of comorbidities treated with mepolizumab at the respiratory outpatient clinic, Policlinico-Vittorio Emanuele, Catania, Italy. Health records of 31 severe asthmatic patients were retrieved and analyzed. Asthma control test (ACT) score, blood eosinophil count, forced expiratory volume in 1 s (FEV
RESULTS
RESULTS
83.87% of patients were classified as responsive to MEPO treatment. Substantial depletion of the blood eosinophils (>80%) was found in 87.1% of patients, FEV
CONCLUSIONS
CONCLUSIONS
MEPO in patients with severe EA is effective regardless of the presence of comorbidities.
Identifiants
pubmed: 32994855
doi: 10.1016/j.waojou.2020.100462
pii: S1939-4551(20)30365-3
pmc: PMC7508691
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100462Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
All the authors declare no competing interests.
Références
Ann Allergy Asthma Immunol. 2011 Dec;107(6):474-9
pubmed: 22123375
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
BMC Pulm Med. 2018 Jul 18;18(1):119
pubmed: 30021546
PLoS One. 2013;8(3):e59872
pubmed: 23544105
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Respir Res. 2019 Jul 30;20(1):169
pubmed: 31362741
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Lancet Respir Med. 2016 Jul;4(7):528-529
pubmed: 27177492
Pulm Pharmacol Ther. 2019 Oct;58:101836
pubmed: 31473366
Drugs Context. 2019 May 27;8:212584
pubmed: 31191705
Expert Rev Respir Med. 2019 Dec;13(12):1205-1212
pubmed: 31592700
Lancet Respir Med. 2016 Jul;4(7):549-556
pubmed: 27177493
J Allergy Clin Immunol. 2009 Oct;124(4):719-23.e1
pubmed: 19767070
Lancet Respir Med. 2017 May;5(5):390-400
pubmed: 28395936
Expert Rev Respir Med. 2011 Jun;5(3):377-93
pubmed: 21702660
Pulm Pharmacol Ther. 2014 Apr;27(2):129-38
pubmed: 24468677
Ann Am Thorac Soc. 2014 Sep;11(7):1011-7
pubmed: 24983709
World Allergy Organ J. 2018 Dec 6;11(1):34
pubmed: 30555618
Curr Opin Allergy Clin Immunol. 2019 Feb;19(1):46-52
pubmed: 30516546
Nat Med. 2012 May 04;18(5):716-25
pubmed: 22561835
J Intern Med. 2012 Aug;272(2):133-43
pubmed: 22640264
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S65-87
pubmed: 22386510
BMC Pulm Med. 2019 Oct 12;19(1):176
pubmed: 31606052
N Engl J Med. 2014 Sep 25;371(13):1189-97
pubmed: 25199060
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
J Asthma. 2019 Sep 3;:1-6
pubmed: 31479312
Clin Exp Allergy. 2020 Jul;50(7):780-788
pubmed: 32347992
Respir Med. 2019 Nov;159:105806
pubmed: 31751853
Pulm Pharmacol Ther. 2018 Dec;53:1-5
pubmed: 30217438
Respir Res. 2012 Feb 01;13:10
pubmed: 22296721
J Asthma Allergy. 2019 Mar 05;12:83-90
pubmed: 30881051